{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-074439","form_type":"8-K","ticker":"ESPR","cik":"0001434868","company_name":"Esperion Therapeutics, Inc.","filed_at":"2023-06-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.857138+00:00","generated_at":"2026-06-13T17:00:17.269171+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Esperion reports 30% MACE-4 risk reduction with bempedoic acid in primary prevention CLEAR Outcomes subanalysis","bullets":["Primary prevention population (4,206 statin-intolerant patients) showed 30% risk reduction in MACE-4 (HR 0.70) vs placebo.","36% MACE-3 risk reduction (HR 0.64) and 39% reduction in CV mortality (HR 0.61).","All-cause mortality reduced by 27% (HR 0.73). LDL-C lowered 21.3% after 6 months; hsCRP lowered 21.5% after 12 months.","Data presented at ADA 2023 and simultaneously published in JAMA on June 24, 2023.","Nearly two-thirds (66.1%) of primary prevention patients had diabetes; safety consistent with prior trials."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-074439","json":"https://secwatch.observer/filing/0001104659-23-074439.json","markdown":"https://secwatch.observer/filing/0001104659-23-074439.md","text":"https://secwatch.observer/filing/0001104659-23-074439.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1434868/000110465923074439/0001104659-23-074439-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1434868/000110465923074439/tm2319637d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T17:00:17.269171+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}